Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cevostamab
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: Daratumumab
DRUG: Elotuzumab
DRUG: Carfilzomib

Sponsor

Hoffmann-La Roche